- Home
- VIGL vs LTRX Comparison
VIGL vs LTRX Comparison
Compare VIGL & LTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- LTRX
- Stock Information
- Founded
- VIGL 2020
- LTRX 1989
- Country
- VIGL United States
- LTRX United States
- Employees
- VIGL N/A
- LTRX N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- LTRX Computer Communications Equipment
- Sector
- VIGL Health Care
- LTRX Telecommunications
- Exchange
- VIGL Nasdaq
- LTRX Nasdaq
- Market Cap
- VIGL 89.3M
- LTRX 106.5M
- IPO Year
- VIGL 2022
- LTRX 2000
- Fundamental
- Price
- VIGL $1.68
- LTRX $2.44
- Analyst Decision
- VIGL Strong Buy
- LTRX Strong Buy
- Analyst Count
- VIGL 5
- LTRX 6
- Target Price
- VIGL $16.33
- LTRX $5.83
- AVG Volume (30 Days)
- VIGL 159.5K
- LTRX 224.1K
- Earning Date
- VIGL 03-13-2025
- LTRX 04-28-2025
- Dividend Yield
- VIGL N/A
- LTRX N/A
- EPS Growth
- VIGL N/A
- LTRX N/A
- EPS
- VIGL N/A
- LTRX N/A
- Revenue
- VIGL N/A
- LTRX $155,842,000.00
- Revenue This Year
- VIGL N/A
- LTRX N/A
- Revenue Next Year
- VIGL N/A
- LTRX $11.33
- P/E Ratio
- VIGL N/A
- LTRX N/A
- Revenue Growth
- VIGL N/A
- LTRX 12.96
- 52 Week Low
- VIGL $1.49
- LTRX $2.41
- 52 Week High
- VIGL $6.06
- LTRX $4.55
- Technical
- Relative Strength Index (RSI)
- VIGL 32.05
- LTRX 32.64
- Support Level
- VIGL $1.74
- LTRX $2.67
- Resistance Level
- VIGL $1.94
- LTRX $2.79
- Average True Range (ATR)
- VIGL 0.16
- LTRX 0.11
- MACD
- VIGL -0.02
- LTRX -0.00
- Stochastic Oscillator
- VIGL 4.51
- LTRX 5.56
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About LTRX Lantronix Inc.
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.